Juli Miller | Head-Investor Relations |
Adrian Rawcliffe | Chief Executive Officer |
Garry Menzel | President and Chief Executive Officer, TCR2 Therapeutics |
Ernie Rodriguez | Cowen |
Mara Goldstein | Mizuho |
Tony Butler | EF Hutton |
Michael Schmidt | Guggenheim |
Jonathan Chang | SVB Securities |
Asthika Goonewardene | Truist Securities |
Kelly Shi | Jefferies |
Soumit Roy | Jones Research |
Yanan Zhu | Wells Fargo Securities |
Peter Lawson | Barclays |
Welcome to Adaptimmune and TCR2 joint webcast to discuss their strategic combination announced earlier this morning.
I will turn the call over to Juli Miller, VP of Investor Relations and Corporate Affairs at Adaptimmune. Juli?
Thank you, operator. Hello.